Exclusive Summary

• - Patent window is open: 300mg/5mL inhalation solution faces no material global patent barriers, enabling rapid registration and distribution.
• - Clear patient pool: ~35,000–80,000 CF patients with chronic P. aeruginosa worldwide, with additional upside from bronchiectasis.
• - Strong clinical standing: first-line inhaled antibiotic in major US/EU guidelines with predictable 28-days-on/28-days-off cyclic use.
• - Compelling economics: typically 50–80% cost savings vs brands, supporting payer adoption and tender wins.
• - Compliance roadmap: China NMPA approved; EU dossier planned for 2025 and site audit in 2026, strengthening global partner confidence.